1)    賀宇彤,等. Risk factors for pulmonary nodules in north China: A prospective cohort study. Lung Cancer. 2018 Jun;120:122-129. (SCI=4.29). 第一作者

2)    賀宇彤,等. Cancer survival in Cixian of China, 2003-2013: a population-based study. Cancer Med. 2018 Apr;7(4):1537-1545. (SCI=3.20) . 通訊作者

3)    賀宇彤,等. Fine particulate matter associated mortality burden of lung cancer in Hebei Province, China. Thoracic Cancer. 2018, 9(7):820-826. (SCI=2.569) 第一作者

4)    賀宇彤,等. Long Noncoding RNA PVT1 as a Novel Predictor of Metastasis, Clinicopathological Characteristics and Prognosis in Human Cancers: a Meta-Analysis. Pathol Oncol Res. 2018. (SCI=1.935) 通訊作者

5)    賀宇彤,等.Patterns of care of nonsmall cell lung cancer patients in China and implications for survival. 2018.(SCI=0.842) 第一作者

6) 賀宇彤, 等. Cancer incidence and mortality in Hebei province, 2013. Medicine. 2017;96(26):e7293. 第一作者 (SCI=2.133)

7）賀宇彤, 等.Evaluation of miR-21 and miR-375 as prognostic biomarkers in oesophageal cancer in high-risk areas in China. Clin Exp Metastasis. 2017;1;34(1):73-84. 第一作者(SCI=2.728)

8）賀宇彤, 等.Using the New CellCollector to Capture Circulating Tumor Cells from Blood in Different Groups of Pulmonary Disease: A Cohort Study. Scientific Reports.2017.第一作者(SCI=4.259)

9）賀宇彤, 等.Esophageal cancer in high-risk areas of China: research progress and challenges. 通訊作者(SCI=2.582)

10）賀宇彤, 等.Research progress on the relationship between zinc deficiency, related microRNAs, and esophageal carcinoma. Thoracic Cancer.2017通訊作者(SCI=1.116)

11) 賀宇彤, 等.The prognostic value of neutrophil to lymphocyte and platelet to lymphocyte ratios for patients with lung cancer. Oncology letters.2017.通訊作者(SCI=1.390)

12)LIANG LIU(劉亮), JING ZUO and GUANGDA WANG. Epigallocatechin 3 gallate suppresses cell proliferation and promotes apoptosis in Ec9706 and Eca109 esophageal carcinoma cells. Oncology letters. 2017,14(4):4391-4395. (通訊作者：劉亮)

13)Liang Liu(劉亮), Yingchao Ju, Jing Wang, Rongmiao Zhou. Epigallocatechin-3-gallate promotes apoptosis and reversal of multidrug resistance in esophageal cancer cells. Pathology-Research and Practice. 2017,213(10): 1242-1250. (通訊作者：劉亮)

14)Lei Wang, Liang Liu(劉亮), Jing Wang, and YueTong Chen. Inhibitory Effect of Artesunate on Growth and Apoptosis of Gastric Cancer Cells. Archives of Medical Research, 2017, 48(7):623-630. (通訊作者：劉亮)

15)Tao Zhou, Liang Liu, Li Yang, Yingchao Ju, Chunxiao Li. The expression of ANXA3 and its relationship with the occurrence and development of breast cancer. JBUON, 2018,23(3):713-719. (通訊作者：劉亮)

16)Lei Wang, Liang Liu*, Yuetong Chen ,Yu Du, Jing Wang, Jianghui Liu. Correlation between adenosine triphosphate (ATP)-binding cassette transporter G2 (ABCG2) and drug resistance of esophageal cancer and reversal of drug resistance by artesunate. Pathology-Research and Practice. 2018, 214(9):1467-1473. (通訊作者：劉亮)

17)Jie Li , Tao Zhou , Liang Liu , YingChao Ju , YueTong Chen , ZiRui Tan and Jing Wang. The regulatory role of Annexin 3 in a nude mouse bearing a subcutaneous xenograft of MDA-MB-231 human breast carcinoma. Pathology-Research and Practice. 2018, 214(10),1719-1725. (通訊作者：劉亮)

18)YueTong Chen, Liang Liu, Jie Li, Yu Du, Jing Wang, JiangHui Liu. E?ects of long noncoding RNA (linc-VLDLR) existing in extracellular vesicles on the occurrence and multidrug resistance of esophageal cancer cells. Pathology-Research and Practice.2019,215 (3):470-477. (通訊作者：劉亮)

19)Wang Jing. CB2 receptor agonist JWH133 activates AMPK to inhibit growth of C6 glioma cells. Open Life Sci, 2019,14:363-375.共同第一作者

20)Wang Jing. Modulation of Cancer Immunotherapy Efficacy by Gut Microbiota. DISCOVERY MEDICINE,2019,27(147): 93-100. 通訊作者